Nyrada, Inc. · ASX:NYR
Nyrada — ShareCafe Hidden Gems Webinar (September 2022)
18 slides from Nyrada's conference presentation, Sep 29, 2022
Slide 1: Presentation to ShareCafe Hidden Gems Webinar
29th September 2022 Sydney, Australia For personal use only Presentation to ShareCafe Hidden Gems Webinar Nyrada Inc (ASX: NYR) is pleased to provide investors with the attached presentation, which will be given by Nyrada CEO, James Bonnar at the ShareCafe Hidden Gems Webinar, from 12.30pm AEST on 3
Slide 2: Forward-Looking Statements
Media Enquiries: For personal use only Catherine Strong Citadel-MAGNUS T: 02 8234 0111 E: cstrong@citadelmagnus.com Forward-Looking Statements This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”,
Slide 3: Improving Lives Through Innovation - Corporate Presentation
For personal use only Improving Lives Through Innovation Corporate Presentation James Bonnar - CEO September 2022 ASX: NYR NYRADA INC (ASX:NYR) Authorised by Mr. John Moore, Non-Executive 1 Chairman, on behalf of the Board. CORPORATE PRESENTATION
Slide 4: Important Notice & Disclaimer
Important Notice & Disclaimer For personal use only This presentation has been prepared by Nyrada Inc (NYR or the Company). It should Although the Company believes that the expectations reflected in the forward-looking not be considered as an offer or invitation to subscribe for, or purchase any sha
Slide 5: Portfolio of Novel High Value Small Molecule Drugs
Portfolio of Novel High Value Small Molecule Drugs For personal use only Target Indication Aim Status Market (US) Cardiovascular Cholesterol Best-in-class small molecule drug to >18m Patients1 Phase I Study: NYX-PCSK9i Lowering disrupt and broaden the class in CV H1 CY2023 Oral PCSK9 inhibitor manag
Slide 6: Commercially Focused Business Model
Commercially Focused Business Model For personal use only • Novel small molecule treatments for serious and life-threatening diseases Focus Area where there is unmet clinical need and large market share potential Development • Advance optimised drug candidates towards a key value inflection point of
Slide 7: Cholesterol-Lowering Drug Program
For personal use only Cholesterol-Lowering Drug Program Novel small molecule PCSK9 Inhibitor
Slide 8: Cholesterol-Lowering Market
Cholesterol-Lowering Market Population, Problem, Opportunity For personal use only 56 million 18.4 million between ages 40 and 75 Unable to achieve treatment eligible LDL-C target despite taking a statin1 62.6 million 27.4 million 1 in 5 patients Americans have high cholesterol1 statin intolerant3 t
Slide 9: Current PCSK9 Injectable Drugs
Current PCSK9 Injectable Drugs Expensive and Inconvenient For personal use only Effective when combined with statin treatment Expensive US$5,800 to US$6,500 per year Inconvenient for patient / poor compliance Expensive to manufacture Insurer / patient co-pay reluctance (US) • Patient convenience: on
Slide 10: Benchmarking Efficacy
Benchmarking Efficacy NYX-PCSK9i +/- Lipitor® in Transgenic Mouse Hyperlipidemia Model For personal use only Study Objective: Results: Determine if additive reduction in total cholesterol can be • NYX-PCSK9i + Lipitor® achieves 65% total achieved with combination statin therapy cholesterol reduction
Slide 11: Efficacy in Model of Atherosclerosis
Efficacy in Model of Atherosclerosis NYX-PCSK9i in Human Tissue-Engineered Blood Vessel Model6 For personal use only Study Design Results: • Researchers at Duke University (US) used human stem cells • Optimised analog of NYX-PCSK9i reduced cell to create tissue-engineered blood vessels (TEBVs), adh
Slide 12: Program Milestones and Path to the Clinic
Program Milestones and Path to the Clinic For personal use only 2H CY2020 1H CY2021 2H CY2021 UPCOMING JUL 2021 DEC 2021 CY2022 - CY2023 DEC 2020 MAY 2021 USPTO Charles River Preclinical studies to commence NYX-PCSK9i shows Potent new drug grants patent for Laboratories in H2 CY2022 57% reduction in
Slide 13: Phase I Study Design
Phase I Study Design For personal use only OBJECTIVES • Evaluate safety, tolerability, and pharmacokinetics of optimised analog of NYX-PCSK9i • Measure changes in LDL-cholesterol in healthy volunteers and exploratory patient population cohorts PARTICIPANTS • 10 cohorts (6 active: 2 placebo per cohor
Slide 14: Corporate Snapshot
For personal use only Corporate Snapshot ASX:NYR NYRADA INC (ASX:NYR) 12 CORPORATE PRESENTATION
Slide 15: Corporate Snapshot
Corporate Snapshot For personal use only Key Metrics Market capitalisation A$20.3M (as at 28 September 2022) Share price A$0.13 (as at 28 September 2022) CDIs free float 156,008,700 Cash at bank 30 June 2022: A$10.8M • Adequate funding for Phase I studies ASX listing January 16, 2020 NYRADA INC (ASX
Slide 16: Management Team with Proven Industry Experience
Management Team with Proven Industry Experience For personal use only High calibre Board with proven track record in realising the value of biotech companies: • John Moore Chairman • Christopher Cox Non-Executive Director James Bonnar - CEO Cameron Jones - CFO Dr Benny Evison - CSO • Marcus Frampton
Slide 17: References
References For personal use only 1 Wong ND et al. Prevalence of the American College of Cardiology/American Heart Association statin eligibility groups, statin use, and low-density lipoprotein cholesterol control in US. J Clin Lipidology. 2016 2 Brain Injury Alliance (Connecticut): http://www.biact.
Slide 18: For personal use only
For personal use only Brain Injury Solution Cholesterol-Lowering Animation Animation @nyrada_inc @nyrada_inc ASX:NYR info@nyrada.com www.nyrada.com NYRADA INC (ASX:NYR) 16 CORPORATE PRESENTATION
Nyrada — ShareCafe Hidden Gems Webinar (September 2022) on 6ix